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Ovarian cancer is the fourth most frequent cause of cancer death in
women and the most fatal gynaecologic malignancy (Storm et al,
1993). At the time of diagnosis approximately 70% to 75% of the
patients already have advanced disease (Thigpen et al, 1995),
evidenced by involvement of pelvic and abdominal organs or of
more distant sites. Current standard treatment of advanced ovarian
carcinoma consists of aggressive primary cytoreductive surgery
followed by systemic platinum-based combination chemotherapy.
After cytoreductive surgery, most patients maintain small amounts
of residual tumour at multiple sites throughout the peritoneal
cavity, which is difficult to evaluate by physical examination and
imaging techniques during subsequent treatment. 
To monitor ovarian cancer patients serum tumour marker CA
125 has been proposed as a supplement to other non-invasive diag-
nostic methods. An important characteristic of CA 125 is the
ability to reflect changes in tumour mass during chemotherapy or
in the follow-up period after completion of therapy. If patients
have elevated serum CA 125 levels at diagnosis, serial serum CA
125 determinations during initial therapy accurately reflect the
disease course in more than 74% of the matched events (clinical
versus marker response, stability or progression) (Tuxen et al,
1995). However, there is no consensus concerning the interpreta-
tion of consecutive tumour marker concentrations and several
different criteria have been proposed (Bast et al, 1983, 1984;
Krebs et al, 1986; Fioretti et al, 1987; Panza et al, 1988; Gadducci
et al, 1990, 1991; Cruickshank et al, 1992; Fioretti et al, 1992;
Rustin et al, 1992; Vergote et al, 1992; Rustin et al, 1993, 1997),
but none are able to eliminate the false positive marker signals as
regards tumour progression. 
The present study was performed to improve the clinical value
of CA 125 monitoring by introduction of a precise definition of
CA 125 progression. We investigated the ability of the serum
tumour marker CA 125 to monitor patients with ovarian cancer
during first-line chemotherapy when the evaluation of CA 125
information was based on the analytical imprecision and the
normal intra-individual biological variation. Additionally, we
compared this approach with other methods of interpreting
changes in CA 125 concentrations. The study was based on our
previously described model for the interpretation of serum CA 125
results based on the analytical imprecision and the average
inherent intra-individual biological variation (Tuxen et al, 2000). 
MATERIALS AND METHODS 
Patients 
255 patients with stage IC-IV ovarian cancer were allocated to the
tumour marker monitoring study. All participated in the North
Thames Ovary Trial, England, of 5 versus 8 courses of carboplatin
400 mg/m2 or cisplatin 75 mg/m2 every 4 weeks. The inclusion
ranged from December 1989 to April 1994. The North Thames
Ovary Trial was approved by the regional Ethical Committees. 48
patients were ineligible for the present study due to early death
(death within the first 4 weeks of treatment) in 3 patients, another
primary cancer in 11, and treatment with monoclonal antibody,
which could cause falsely elevated CA 125 levels (Boscato and
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cient sampling (<3 CA 125 samples) and in 3 the last sample was
taken more than 3 months prior to clinical progressive disease
(clinical PD). Thus, 207 patients were considered eligible for
tumour marker assessment. 
Analytical methods 
A total of 1366 CA 125 samples were obtained during first-line
chemotherapy with a median of 6 samples per patient. Each
sample from one individual patient was assayed in duplicate in
different assay runs. 
Serum CA 125 was initially determined by ELSA-CA 125, an
immunoradiometric assay from CIS Bio International (Gif-sur-
Yvette Cédex, France). The applied cut-off value was 35 U/mLas
recommended by Bast et al (1983) and the manufacturer (personal
communication).
Since August 1992, CA 125 has been measured by the Cobas
Core CA 125 II EIA assay, a one-step solid-phase enzyme
immunoassay based on the sandwich principle from Roche
Diagnostic Systems (Basel, Switzerland). The cut-off value
recommended by the manufacturer was 35 U/mL (Roche
Diagnostic Systems, 1996). 
Procedure for matching clinical and CA 125 information
and definitions of CA 125 progression criteria 
The results of the tumour marker assessment were compared 
retrospectively with the clinical data. No clinical evaluation 
of the status of the disease was performed during first-line
chemotherapy. However, if a patient developed signs of clinical
PD, appropriate clinical examinations were performed and the
date of progression registered. Thus, only data of clinical PD were
available for first-line chemotherapy. 
A change between 2 consecutive marker concentrations during
monitoring of patients with ovarian cancer is statistically signifi-
cant, if the difference (the critical difference) exceeds √ 2´Z´
√ (CVA
2 + CVI
2) (Fraser et al, 1990; Fraser and Petersen, 1991). 
√ 2 is a constant (2 measurements). Z is the Z-statistic, which
depends on the probability selected for significance and on whether
the change expected is unidirectional (only one option, either an
increment or a decrement) or bidirectional (2 options because it is
unknown whether the concentration will rise or fall). Z equals 1.65
for unidirectional and 1.96 for bidirectional changes, for which
less than 5% of differences will exceed this value during steady
state conditions. CVI, which is the average intra-individual biolog-
ical variation of CA 125 was calculated previously on basis of 25
patients with both clinical disease and marker concentrations in a
steady state. The CVI was 24% (Tuxen et al, 2000). CVA, the
analytical imprecision corresponding to a patient’s CA 125 base-
line concentration, was read from the respective precision profiles
of the total analytical variation for CA 125. The total analytical
variation comprised both the intra- and the inter-assay variation.
The baseline concentration is a CA 125 concentration, from which
an increment or a decrement starts. According to this approach the
critical difference is variable and depends on the analytical impre-
cision at the considered concentration level. 
Assessment of CA 125 data was based on the magnitude of the
critical difference, the duration of the difference, and the cut-off
value (Sölétormos et al, 1993a, 1996). The duration of the differ-
ence was decided to be of at least 28 days due to a practical
approach as the chemotherapy cycles were given every 4 weeks
and CA 125 samples normally taken on the day of treatment. Thus,
the criteria for marker PD depended on whether the marker incre-
ment started below or above the cut-off value. 
Criterion 1: for increment starting below the cut-off value the
criteria for CA 125 PD were: a significant increment from below
to above the cut-off value during the first time interval of ³ 28
days. The increment during the first time interval was confirmed
by a further measurement during the second time interval of ³ 28
days. It was not required that a further increase during the second
time interval significantly exceeded the concentration obtained
during the first time interval (Figure 1A). 
Criterion 2: for increment starting above the cut-off value the
criteria for CA 125 PD were: an increment from the baseline
concentration during the first time interval of ³ 28 days, which did
not have to be significant. However, the concentration obtained
during the second time interval of ³ 28 days should significantly
exceed the baseline concentration (Figure 1B). 
The calculated date of marker PD was the date of the first sample,
which indicated progression: the second sample if the critical
difference was achieved during the first time interval (Figure 1A
and 1B), and the third sample if the critical difference was
achieved during the second time interval (Figure 1B). For the sake
of simplicity these two criteria will hereafter be called ‘the
progression criteria 1 and 2’. CA 125 data were defined as non-
assessable when all concentrations remained below the cut-off
value or fluctuated across the cut-off value without achieving the
critical difference (Figure 1C). 
Beside the above-mentioned criteria, the performance of an
alternative criterion based upon an increment of 2.5 times the base-
line concentration was also assessed (Figure 2). According to this
criterion CA 125 predicted progression if the baseline concentra-
tion increased 2.5 times during the first time interval of ³28 days
and the increase continued during the second time interval of ³28
days. If the baseline concentration was below the cut-off value, the
increment during the first time interval had to exceed the cut-off
value. There was no requirement as regards the magnitude of the
increment obtained during the second time interval. The increase of
2.5 times the baseline concentration was equal to the critical differ-
ence of approximately 86% as a change between two CA 125
concentrations, x1 and x2, was calculated as (x2 – x1)/√ (x1+x2). The
calculated date of marker PD was the date of the second sample.
For the sake of simplicity this criterion will hereafter be called ‘the
elaborated progression criterion’. As previously, CA 125 data were
defined as non-assessable when all concentrations remained below
the cut-off value or fluctuated across the cut-off value without
fulfilling the progression criterion (Figure 1C). 
Statistics 
Confidence intervals for frequencies were calculated according to
Armitage and Berry (1994). 
RESULTS 
The progression criteria 1 and 2 
The clinical and marker data for all patients were updated in April
1998. The pretreatment characteristics of the 207 eligible patients
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criteria 1 and 2, 16 patients were found marker non-assessable
(Figure 1C). Additionally, the CA 125 profiles of 18 patients with
clinical PD during the study period did not fulfil the progression
criteria (Figure 1A and 1B) as the patients had an increment of CA
125 concentrations exceeding the critical difference but without a
confirmatory sample due to discontinuation of marker monitoring
or due to start of second-line treatment. These 16 patients were
also excluded from the marker analysis. Of the remaining 173
assessable patients, 24 developed clinical PD during first-line
chemotherapy. The distribution of all patients evaluated for entry
into the CA 125 monitoring study is presented in Table 2. 
The results of the matching procedure of clinical and CA 125
information obtained during first-line chemotherapy are shown in
Table 3. CA 125 correctly identified 45.8% of the patients with, and
99.3% of the patients without clinical PD. A patient with marker PD
had a 91.7% probability of developing clinical PD, whereas a
patient without marker PD had a 91.9% probability of being without
clinical PD. CA 125 gave a false-positive prediction of progression
in one patient during treatment. The patient had an unusual marker
profile with considerably fluctuating CA 125 levels during the
whole study period. CA 125 concentrations ranged from 56 to 185
U/mL–1 during chemotherapy and from 45 to 130 U/mL during
follow-up. Despite relatively high marker concentrations, the
patient did not experience clinical PD during first-line chemo-
therapy or during a subsequent follow-up period of 40.4 months. 
Marker PD preceded clinical PD in 10 patients with a median
positive lead time of 48.5 days (range 1–79) (Table 2). One patient
had no lead time as the date of marker PD coincided with the date
of clinical PD. In additional 2 patients, clinical PD preceded
marker PD with negative lead times of 11 and 132 days, respec-
tively. However, CA 125 was not measured at the time of clinical
PD in the patient with a negative lead time of 11 days. 
Discarded criteria 
In a number of previous publications, changes in serum CA 125
results were considered significant if the prechange concentration
increased by 50% (Krebs et al, 1986; Vergote et al, 1992) or by
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Table 1 Pretreatment characteristics of 207 ovarian cancer patients eligible
for CA 125 monitoring during first-line chemotherapy 
Characteristic  Number of patients (% of total) 
Age  median 62 years (range
17–79 years) 
Performance status 
0 129  (62.3) 
1 71  (34.3) 
2 7  (3.4) 
FIGO stage 
IC 22  (10.6) 
IIA 1  (0.5) 
IIB 13  (6.3) 
IIC 14  (6.8) 
IIIA 3  (1.4) 
IIIB 14  (6.8) 
IIIC 117  (56.5) 
IV 23  (11.1) 
Histologic type 
Serous 92  (44.4) 
Mucinous 14  (6.8) 
Endometrioid 26  (12.6) 
Clear cell  17 (8.2) 
Undifferentiated 26  (12.6) 
Mixed 15  (7.2) 
Unclassified 17  (8.2) 
Grade 
Well differentiated (grade I)  22 (10.6) 
Moderately differentiated (grade II)  58 (28.0) 
Poorly differentiated (grade III)  71 (34.3) 
Unclassified 7  (3.4) 
Well to moderately differentiated (grade I–II)  10 (4.8) 
Moderately to poorly differentiated (grade II–III)  29 (14.0) 
Well to poorly differentiated (grade I–III)  3 (1.4) 
Borderline 7  (3.4) 
Primary residual tumour size 
No residual tumour, negative cytology  14 (6.8) 
No residual tumour, positive cytology  15 (7.2) 
No residual tumour, cytology unknown  12 (5.8) 
<2 cm residual disease, single site  10 (4.8) 
<2 cm residual disease, multiple sites  70 (33.8) 
³2 cm residual disease  60 (29.0) 
Inoperable 26  (12.6) 
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Figure 1 Progression criteria for the serum tumour marker CA 125. (A) For increment starting below the cut-off value a significant increment from the baseline
concentration occurred during the first time interval of ³ 28 days and was confirmed by a further measurement during the second time interval of ³ 28 days. The
significant increment during the first time interval had to exceed the cut-off value. The significant increment was not required for the second time interval. (B) For
increment starting above the cut-off value an increment obtained during the first time interval of ³ 28 days did not have to be significant. However, a further
measurement during the second time interval of ³ 28 days had to significantly exceed the baseline concentration. (C) Non-assessable CA 125 data: all
concentrations remained below the cut-off value or fluctuated across the cut-off value100% (Bast et al, 1983, 1984; Fioretti et al, 1987; Panza et al,
1988; Gadducci et al, 1990, 1991; Cruickshank et al, 1992; Fioretti
et al, 1992). However, these criteria produce too many false-
positive results because in many cases the increase does not exceed
the fluctuations attributable to analytical and biological variability,
e.g. the increase is lower than the critical difference calculated on
basis of biological and analytical variation in these cases. 
As the doubling of the baseline CA 125 concentration is not
always significant, an increment of 2.5 times the prechange
concentration has also been considered. An increment of 2.5 times
the prechange concentration invariably exceeds the critical differ-
ence. The criterion may, however, produce a false-positive predic-
tion of progression in many patients as single increment of CA 125
may be misleading. 
An increment of 2.5 times the baseline concentration
confirmed by a third measurement 
The CA 125 progression criterion based upon an increment of 2.5
times the baseline concentration was further developed using 2
increasing CA 125 values, the second one for a confirmation of
progression (Figure 2). This approach was developed in an attempt
to follow the recommendations of the consensus committee on
advanced epithelial ovarian cancer who dissuaded clinical deci-
sion making based on interpretation of a single CA 125 increment
(Berek et al, 1999), because a single elevated concentration may
be caused by an unspecific fluctuation not related to a change in
disease activity. 
Out of 207 patients eligible for CA 125 assessment 39 patients
were excluded from the marker analysis, 16 due to a non-assessable
marker profile (Figure 1C) and 23 due to a missing confirmatory
sample. The patients from the latter group, all with clinical PD
during the study period, had an increment of CA 125 concentra-
tions exceeding an increment of 2.5 times the baseline concentra-
tion but were without a confirmatory sample measured due to
discontinuation of marker monitoring or due to start of second-line
treatment. Among the remaining 168 assessable patients, 24 devel-
oped clinical PD during first-line chemotherapy. The distribution
of all patients evaluated for entry into the CA 125 monitoring
study is presented in Table 4. 
The ability of serum CA 125 to predict progressive disease
during first-line chemotherapy is presented in Table 5. There was a
33.3% and 100.0% concordance between the clinical and marker
information in patients with and without clinical PD, respectively.
No false-positive and 16 false-negative results were obtained
during treatment. Therefore, marker PD was associated with a
100.0% probability of clinical PD, whereas CA 125 concentrations
remaining below the cut-off value were associated with a 90.0%
probability of being without clinical PD. 
Among the 24 patients with clinical PD, 7 patients had early
marker PD with a median positive lead time of 41 days (range
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Table 3 The ability of serum CA 125 to predict progressive disease during
first-line chemotherapy among 173 ovarian cancer patients if marker
assessment was based upon the progression criteria 1 and 2 
Characteristic CA  125 
TP 11 
FN 13 
TN 148 
FP 1 
SE 45.8  [25.9–65.8] 
SP 99.3  [96.3–99.9] 
PPV 91.7  [61.5–99.8] 
NPV 91.9  [87.7–96.1] 
E 91.9  [87.8–96.0] 
Median lead time for true positive results, days (range)  41 (0 to + 79) 
TP – true positive results; FP – false positive results; TN – true negative
results; FN – false negative results; SE – sensitivity (%); SP – specificity (%); 
PPV – positive predictive value (%); NPV – negative predictive value (%); 
E – efficiency (%); [] – two-sided 95% confidence intervals (%). 24 patients
developed clinical progressive disease during first-line chemotherapy. 
Table 2 The distribution of 255 patients with ovarian cancer allocated to the CA 125 monitoring study. Marker assessment was based on the progression
criteria 1 and 2 
255 patients entered  ® 48 patients were ineligible for CA 125 assessment: 
the North Thames Ovary Trial  3 patients – early death 
11 patients – another primary cancer 
13 patients – treatment with monoclonal antibody 
18 patients – insufficient sampling (<3 samples) 
3 patients – last sample drawn more than 3 months prior to clinical PD 
¯
207 patients were eligible for CA 125 assessment  ® 16 patients were non-assessable because CA 125 concentration continuously
remained below the cut-off value (2 patients with and 14 patients without clinical
PD during first-line therapy). 
18 patients with clinical PD were non-assessable because no confirmatory
sample was measured (2 patients with and 16 patients without clinical PD during
first-line therapy) 
¯
173 assessable patients were monitored   ® 24 patients developed clinical PD: 
during first-line chemotherapy 10 patients – marker PD with a positive lead time 
1 patient – marker PD with zero lead time 
1 patient – marker PD with a negative lead time as no measurement was
taken at the time of clinical PD 
1 patient – marker PD with a negative lead time due to clinical PD preceding
marker PD 
11 patients – never marker PD 
clinical PD – clinical progressive disease; marker PD – marker progression. 1–70); in one patient with no lead time CA 125 became elevated at
the time of clinical PD (Table 4). In 2 patients CA 125 increased
after the detection of progression by other techniques giving nega-
tive lead times of 21 and 167 days, respectively. 
DISCUSSION 
The consensus committee on advanced epithelial ovarian cancer
has recently stated that the tumour marker CA 125 has the poten-
tial to play an important role in individual patient management
(Berek et al, 1999). The marker may be: (1) an accurate early indi-
cator of treatment failure during front-line therapy, (2) of value in
confirmation of relapse, and (3) used during relapse therapy as an
aid to decision making about continuation of therapy. However,
there is no consensus concerning the interpretation of serial CA
125 measurements. Therefore, if CA 125 is to be implemented in
routine clinical situations, a precise definition of CA 125 response
and progression is necessary. 
In previous publications changes in CA 125 concentrations have
usually been evaluated with reference to empirical criteria, such as
an arbitrary percentage of change between consecutive samples or
as an increase of concentrations to above the cut-off value. In most
studies CA 125 indicated progressive disease if a prechange
concentration increased by 50% (Krebs et al, 1986; Vergote et al,
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Table 4 The distribution of 255 patients with ovarian cancer allocated to the CA 125 monitoring study. Marker assessment was based upon an increment of
2.5 times the baseline concentration confirmed by a third measurement 
255 patients entered  ® 48 patients were ineligible for CA 125 assessment: 
the North Thames Ovary Trial 3 patients – early death 
11 patients – another primary cancer 
13 patients – treatment with monoclonal antibody 
18 patients – insufficient sampling (< 3 samples) 
3 patients – last sample drawn more than 3 months prior to clinical PD 
¯
207 patients were eligible for CA 125 assessment  ® 16 patients were non-assessable because CA 125 concentrations continuously
remained below the cut-off value (2 patients with and 14 patients without clinical
PD during first-line therapy). 
23 patients with clinical PD were non-assessable because no confirmatory
sample was measured (2 patients with and 21 patients without clinical PD during
first-line therapy). 
¯
168 assessable patients were monitored   ® 24 patients developed clinical PD: 
during first-line chemotherapy 7 patients – marker PD with a positive lead time 
1 patient – marker PD with zero lead time 
2 patients – marker PD with a negative lead time due to clinical PD
preceding marker PD 
14 patients – never marker PD 
clinical PD – clinical progressive disease; marker PD – marker progression. 
Table 5 The ability of serum CA 125 to predict progressive disease during
first-line chemotherapy among 168 ovarian cancer patients if marker
assessment was based upon an increment of 2.5 times the baseline
concentration confirmed by a third measurement 
Characteristic CA  125 
TP 8 
FN 16 
TN 144 
FP 0 
SE 33.3  [15.6–55.3] 
SP  100.0 [> 97.9]* 
PPV  100.0 [> 68.8]* 
NPV 90.0  [85.4–94.6] 
E 90.5  [86.0–94.9] 
Median lead time for true positive results, days (range)  35 (0 to + 70) 
TP – true positive results; FP – false positive results; TN – true negative
results; FN – false negative results; SE – sensitivity (%); SP – specificity (%); 
PPV – positive predictive value (%); NPV – negative predictive value (%); 
E – efficiency (%); [] – two-sided 95% confidence intervals (%); * – one-sided
95% confidence intervals (%). 24 patients developed clinical progressive
disease during first-line chemotherapy. 
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Figure 2 The progression criterion for the serum tumor marker CA 125
based upon an increment of 2.5 times the baseline concentration confirmed
by a third measurement. An increment of 2.5 times the baseline
concentration occurred during the first time interval of ³ 28 days and an
increase continued during the second time interval of ³ 28 days. If the
baseline concentration was below the cut-off value, the increment during the
first time interval had to exceed the cut-off value. There was no requirement
as regards the magnitude of the increment obtained during the second time
interval1992) or by 100% (Bast et al, 1983, 1984; Fioretti et al, 1987;
Panza et al, 1988; Gadducci et al, 1990, 1991; Cruickshank et al,
1992; Fioretti et al, 1992). It has also been suggested that CA 125
indicated progression if: (1) after 2 fluctuating concentrations a
third concentration increased by 25% as compared to sample 1 and
2 and was confirmed by a fourth measurement, (2) there was a
50% increase over 3 samples, or (3) if there was a persistent eleva-
tion of CA 125 over 100 U/mL for more than 2 months without a
50% decrease (Rustin et al, 1993). Other investigators suggested
progression criteria that were valid only during follow-up of
patients where CA 125 concentrations had decreased to below the
cut-off value after initial chemotherapy. According to these
suggestions a positive CA 125 signal of progression was either
based upon a single increment above the cut-off value (Niloff et al,
1986; van der Burg et al, 1990; Hising et al, 1991; Ward et al,
1993; Gard and Houghton, 1994), or upon an increase of concen-
trations to twice the upper limit of normal (Rustin et al, 1996).
Thus, several empirical criteria for CA 125 progression have been
applied, but none have been precise enough to eliminate false-
positive results. Therefore it may be suggested, that a number of
parameters should be taken into account for interpretation of CA
125 data to discriminate between variations due to the natural
history of malignancy and effective therapy from those arising
from other causes. Parameters such as analytical imprecision and
intra-individual biological variation, which also influence marker
concentrations, have not previously been considered for tumour
marker assessment during monitoring of ovarian cancer. In the
present study, a change in CA 125 concentrations had to exceed
the variability accounted for by both biological fluctuation and
analytical imprecision. The approach has been suggested by other
investigators (Browning, 1987; Browning and McFarlane, 1990;
Sölétormos et al, 1993b; Gion et al, 1995; Plebani et al, 1996) and
tested in monitoring studies of breast cancer (Sölétormos et al,
1993a, 1996). Additionally, the duration of a change in concentra-
tions and the cut-off value were also incorporated as parameters in
the current proposed progression criteria. The progression criteria
1 and 2 included 2 different patterns of increasing CA 125 concen-
trations: a fast and a slow rise pattern (Figure 1A and 1B)
reflecting the fast and indolent growth of progressive disease. 
By considering the above-mentioned parameters in the progres-
sion criteria 1 and 2 the number of false-positive results was
diminished but not eliminated (Table 3). CA 125 gave a false-
positive prediction of progression in one patient during treatment.
The patient had unusual marker profiles with considerably fluctu-
ating CA 125 concentrations, all above the cut-off value despite
clinical non-progression. It is well known that coexisting benign
disease as e.g. liver cirrhosis or peritonitis, may cause elevated CA
125 concentrations (Ruibal et al, 1984; Molina et al, 1991;
Collazos et al, 1992). False-positive results may also be due to an
underestimation of the critical difference for the individual patient
by application of the population-based average intra-individual
biological variation. Assessment of the intra-individual biological
variation separately for each patient would probably be more rele-
vant, but it is difficult to perform, as it requires a collection of
several consecutive measurements during steady state conditions. 
Application of the progression definition based upon an incre-
ment of 2.5 times the baseline concentration confirmed by a third
measurement required a greater magnitude of the critical differ-
ence as compared to the progression criteria 1 and 2 and reduced
the number of false-positive results (Table 5). Generally, fewer
false-positive results give higher specificity and positive
predictive value, albeit at the expense of fewer true-positive
results, implying lower sensitivity. Knowledge of this relationship
is important, as the selection of marker assessment criteria should
partly depend on whether a high sensitivity or a high specificity 
is considered important for the specific clinical monitoring 
situation. The applied criteria also have an impact on the length 
of lead times. The elaborated progression definition gave 
shorter lead times as compared to the progression criteria 1 and 2
(Table 3 and 5). However, differences in lead times of 6 days are
clinically irrelevant. 
Other criteria based upon a 50% or 100% increment of a
prechange concentration were also taken into consideration in the
present study. The definitions were, however, too unprecise
producing too many false-positive CA 125 signals. The doubling
of a prechange concentration of other tumour markers, CA 15.3
and CEA, was, however, successfully applied in monitoring
studies of patients with breast cancer (Sölétormos et al, 1993a,
1996). The discrepancy concerning the utility of the doubling
criterion reported by Sölétormos et al (1993a, 1996) as compared
to the present investigation was due to the magnitude of the intra-
individual biological variation of the tested markers. The intra-
individual biological variation of CA 15–3 and CEA was
considerably lower than the variation of CA 125 resulting in a crit-
ical difference which was lower than a doubling of concentration.
Thus, the doubling of CA 15.3 and CEA concentration was always
significant contrary to the doubling of CA 125 concentration. 
The main purpose of this study was to evaluate the ability of CA
125 to provide reliable information about progressive disease
during postoperative treatment. The results indicated that CA 125
was a reliable predictor of progressive disease. A patient with clin-
ically suspected progression during first-line chemotherapy had a
greater than 91% probability of tumour growth if CA 125 indi-
cated progression using the progression criteria 1 and 2 (Table 3).
The probability raised to 100% if the progression definition was
based upon an increment of 2.5 times the baseline concentration
confirmed by a third measurement (Table 5). 
In conclusion CA 125 gave reliable prediction of progressive
disease during monitoring of first-line chemotherapy. The present
results indicate a high applicability of the progression criteria 1
and 2 as well as the criterion based upon an increment of 2.5 times
the baseline concentration confirmed by a third measurement
during CA 125 monitoring of patients with ovarian cancer. A
further analysis of data from the follow-up period is near comple-
tion and will hopefully provide further objective information
regarding the value of well defined marker progression criteria. 
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